On the HCPLive Ulcerative Colitis condition center page, resources on the topics of medical news and expert insight into colitis can be found. Content includes articles, interviews, videos, podcasts, and breaking news on UC research, treatment, and drug development.
September 11th 2024
The decision is based on rates of clinical and endoscopic remission with guselkumab in the ongoing phase 2b/3 QUASAR study.
Thiopurine Metabolic Monitoring Leads to Higher Remission of IBD
Repeated metabolite monitoring with subsequent dose optimization resulted in 67.2% of patients achieving therapeutic levels after 1 year and 87.8% of patients achieving steroid-free remission, while 90% had no therapy escalation or surgery.